Use of hormone replacement therapy, 1998-2007: Sustained impact of the women's health initiative findings

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 251-258

  Silverman, Barbara G ^a   Kokia, Ehud S ^a  

^a MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

Hormone replacement therapy; Israel; Pharmacoepidemiology

Indexed keywords

ESTROGEN; TIBOLONE;

ADULT; AGED; ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HORMONE SUBSTITUTION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PURCHASING; TREATMENT DURATION; WOMEN'S HEALTH;

ATTITUDE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; ISRAEL; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY;

EID: 60349105090     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L438     Document Type: Article

References (29)

1. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-41.
2. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Washington, DC: Office of Disease Prevention and Health Promotion, 1996.
3. Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34-40.
4. Grodstein F, Manson JE, Colditz GA, Willett WC, Spelzer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
5. Grady D, Rubin SM, Pettiti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
6. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-53.
7. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
8. Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 2005;14:171-6.
9. Merom D, Ifrah A, Cohen-Manheim I, Chinich A, Green MS. Factors predicting current use of hormone-replacement therapy among menopausal Jewish women in Israel. The National Women's Health Interview Survey, 1998. Isr Med Assoc J 2002;4:671-6.
10. Vinker S, Kaplan B, Yaphe J, et al. Use of hormone replacement therapy by menopausal women in six family-practice teaching clinics in Israel. Climacteric 2003;6:75-80.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
12. US Preventive Services Task Force. Hormone therapy for prevention of chronic conditions in postmenopausal women: recommendations from the US Preventive Services Task Force. Ann Intern Med 2005;142:855-60.
13. National Institutes of Health State of the Science Panel. Management of menopause-related symptoms. Ann Intern Med 2005;142:1003-13.
14. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004;11:589-600.
15. ACOG Task Force on Hormone Therapy. Hormone therapy: executive summary. Obstet Gynecol 2004;104(4 suppl):1S-4S.
16. Hartsfield CL, Connelly MT, Newton KM, Andrade SE, Wei F, Buist DS. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. J Natl Cancer Inst Monogr 2005;35:113-5.
17. Grady D, Barrett-Connor E. Postmenopausal hormone therapy. Br Med J 2007;334:860-1.
18. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983-8.
19. Hing E, Brett KM. Changes in US prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006;108:33-40.
20. Buist DSM, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-50.
21. Menon U, Burnell M, Sharma A, et al.; UKCTOCS group. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007;14:462-7.
22. Parazzini F; Progetto Menopausa Italia Study group. Trends of determinants of hormone therapy use in Italian women attending menopause clinics, 1997-2003. Menopause 2008;15:164-70.
23. Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts TCG, de Jong-van den Berg LTW. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005;60:641-7.
24. Wegienka G, Havstad S, Kelsey JL. Menopausal hormone therapy in a health maintenance organization before and after Women's Health Initiative hormone trials termination. J Womens Health 2006;15:369-78.
25. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004;140:184-8.
26. Grady D. Management of menopausal symptoms. N Engl J Med 2006;355:2338-47.
27. Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy: a population-based study. J Gen Intern Med 2006;20:1026-31.
28. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23.
29. Cummings SR, Ettinger B, Delmas PD, et al., for the LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.